Home › NDC Lookup › RxCUI directory › RxCUI 1741046

24 HR tofacitinib 11 MG Extended Release Oral Tablet — RxCUI 1741046

RxNorm drug concept · Semantic clinical drug
RxCUI 1741046 Semantic clinical drug · SCD ● Current RxNorm concept 22 FDA products 26 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1741046
Official name24 HR tofacitinib 11 MG Extended Release Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known astofacitinib 11 MG 24HR Extended Release Oral Tablet; tofacitinib 11 MG (as tofacitinib citrate 17.77 MG) 24 HR Extended Release Oral Tablet
FDA products mapped22
Package NDCs mapped26
Reported Medicaid activity (SDUD)41,140 prescriptions · 51 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Tofacitinib: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It treats rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and ulcerative colitis in adults, usually after a TNF blocker didn't work or wasn't tolerated. Xeljanz a...
  • You take it by mouth. Tablets and solution are usually taken twice a day, and extended-release tablets once a day. It can be taken with or without food. Follow your prescriber's di...
  • Colds, stuffy or sore nose and throat, diarrhea, and headache are most common. Some people with ulcerative colitis also get rash, shingles, or higher cholesterol. Call your doctor...
  • Get help right away for chest pain, stroke symptoms, sudden shortness of breath, or leg swelling and pain, which can signal a clot or heart problem. Also report new belly pain, sig...
📖 Read our full Tofacitinib guide →

🕸️ Concept Web — How 24 HR tofacitinib 11 MG Extended Release Oral Ta... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 24 HR tofacitinib 11 MG Extended Release Oral Tablet RxCUI 1741046

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Tofacitinib 1357536
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Xeljanz 1357542
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Tofacitinib Extended Release Oral Tablet 1741045
    • Tofacitinib Oral Product 1357538
    • Tofacitinib Pill 1357539
    • Tofacitinib Extended Release Oral Tablet [Xeljanz] 1741048
    • Xeljanz Oral Product 1357545
    • Xeljanz Pill 1357546
    • Extended Release Oral Tablet 316945
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Tofacitinib 11 MG SCDC · 1741044
  • Tofacitinib Extended Release Oral Tablet SCDF · 1741045
  • Tofacitinib Oral Product SCDG · 1357538
  • Tofacitinib Pill SCDG · 1357539

Brand-Name Concepts

📦 FDA Products & Package NDCs

22 products · 26 package NDCs
26 package NDCs map to RxCUI 1741046 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00069-0501-30 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0069-0... XELJANZ XR Pfizer Laboratories Div Pfizer Inc 2016-03-07
00069-0502-30 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0069-0... XELJANZ XR Pfizer Laboratories Div Pfizer Inc 2020-01-21
00069-1001-01 60 TABLET, FILM COATED in 1 BOTTLE (0069-1001-01) XELJANZ Pfizer Laboratories Div Pfizer Inc 2012-11-09
00069-1002-01 60 TABLET, FILM COATED in 1 BOTTLE (0069-1002-01) XELJANZ Pfizer Laboratories Div Pfizer Inc 2018-07-02
00069-1029-02 1 BOTTLE in 1 CARTON (0069-1029-02) / 240 mL in 1 BOTTLE (0... XELJANZ Pfizer Laboratories Div Pfizer Inc 2021-02-08
00574-1811-30 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0574-1... TOFACITINIB CITRATE Padagis US LLC 2026-06-15
27241-0270-30 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (27241-270-30) Tofacitinib Ajanta Pharma USA Inc. 2026-06-03
42799-0970-30 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (42799-... Tofacitinib Edenbridge Pharmaceuticals LLC. 2026-06-03
59651-0685-30 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (59651-685-30) TOFACITINIB Aurobindo Pharma Limited 2026-06-03
60505-4858-03 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (60505-... Tofacitinib Apotex Corp. 2026-06-09
63539-0012-02 60 TABLET, FILM COATED in 1 BOTTLE (63539-012-02) XELJANZ U.S. Pharmaceuticals 2012-11-08
63539-0016-02 60 TABLET, FILM COATED in 1 BOTTLE (63539-016-02) XELJANZ U.S. Pharmaceuticals 2018-07-02
63539-0029-02 1 BOTTLE in 1 CARTON (63539-029-02) / 240 mL in 1 BOTTLE (6... XELJANZ U.S. Pharmaceuticals 2021-02-08
63539-0501-30 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (63539-501-30) XELJANZ XR U.S. Pharmaceuticals 2016-03-07
63539-0502-30 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (63539-502-30) XELJANZ XR U.S. Pharmaceuticals 2020-01-21
70377-0057-11 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (70377-... Tofacitinib XR Biocon Pharma Inc 2026-06-03
70710-1353-03 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (70710-... tofacitinib Zydus Pharmaceuticals USA Inc. 2026-05-20
70710-1353-09 90 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (70710-... tofacitinib Zydus Pharmaceuticals USA Inc. 2026-05-20
70710-1727-03 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (70710-... tofacitinib Zydus Pharmaceuticals USA Inc. 2026-05-20
70710-1727-09 90 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (70710-... tofacitinib Zydus Pharmaceuticals USA Inc. 2026-05-20
70771-1627-03 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (70771-... tofacitinib Zydus Lifesciences Limited 2026-05-20
70771-1627-09 90 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (70771-... tofacitinib Zydus Lifesciences Limited 2026-05-20
70771-1628-03 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (70771-... tofacitinib Zydus Lifesciences Limited 2026-05-20
70771-1628-09 90 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (70771-... tofacitinib Zydus Lifesciences Limited 2026-05-20
73190-0102-30 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (73190-... Tofacitinib AvKARE 2026-06-24
76282-0816-30 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (76282-... TOFACITINIB Exelan pharmaceuticals,Inc 2026-06-10
Observed labelers: Pfizer Laboratories Div Pfizer Inc (5) · U.S. Pharmaceuticals (5) · Zydus Lifesciences Limited (4) · Zydus Pharmaceuticals USA Inc. (4) · Ajanta Pharma USA Inc. (1) · Apotex Corp. (1) · +6 more — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.